

Special Issue

CAR T Therapy of Solid Cancers: Problems and Progress

Message from the Guest Editors

CAR T cell therapy has revolutionized the treatment of hematological malignancies; however, this clinical success has yet to be seen in the treatment of solid cancers. The major issues presented by solid tumors include trafficking to and penetration into the tumor, and CAR T cell cytotoxic function within the tumor microenvironment. The reasons for this lack of efficacy appear to be a combination of a powerful immunosuppressive environment driven by multiple elements of the innate and adaptive immune system, in addition to the physical characteristics of the tumor microenvironment, such as desmoplasia and the net positive pressure. To overcome these challenges, we must investigate the biology of CAR T-cells within immuno-competent models. In this Special Issue of *Cancers*, entitled “CAR T therapy of solid cancers: Problems and Progress”, we invite experts in the field, many of whom employ syngeneic solid tumor models in mice, to submit articles in the hope that together we can begin to resolve the current lack of clinical success regarding the application of CAR T-cell therapy in solid cancers.

Guest Editors

Prof. Dr. John F. Marshall

Centre for Tumour Biology, Barts Cancer Institute, Queen Mary University of London, London EC1M 6BQ, UK

Dr. Lauren Cutmore

Centre for Tumour Biology, Barts Cancer Institute, Queen Mary University of London, London EC1M 6BQ, UK

Deadline for manuscript submissions

closed (30 June 2025)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/184369

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)